Arsenic-induced dysfunction in relaxation of blood vessels

Environmental Health Perspectives

Volumn 111, Issue 4, 2003, Pages 513-517

  Lee, Moo Yeol ^a   Jung, Byung In ^a   Chung, Seung Min ^a   Bae, Ok Nam ^a   Lee, Joo Young ^a   Park, Jung Duck ^b   Yang, Ji Sun ^c   Lee, Hyomin ^c   Chung, Jin Ho ^a  

^a Seoul National University   (South Korea)

^b Chung Ang University   (South Korea)

^c National Institute of Toxicological Research   (South Korea)

Author keywords

Arsenic; Arsenite; Blood vessels; Cardiovascular disease; Endothelial nitric oxide synthase; Nitric oxide; Vasorelaxation

Indexed keywords

8 BROMO CYCLIC AMP; ACETYLCHOLINE; ARSENIC; ARSENIC TRIOXIDE; CYCLIC GMP; NITRIC OXIDE DONOR; NITRIC OXIDE SYNTHASE; NITROPRUSSIDE SODIUM;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BLOOD PRESSURE; BLOOD VESSEL TONE; CARDIOVASCULAR DISEASE; CELL CULTURE; CELL ISOLATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA ANALYSIS; ENDOTHELIUM CELL; ENVIRONMENTAL EXPOSURE; ENZYME ACTIVITY; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SMOOTH MUSCLE FIBER; STATISTICAL SIGNIFICANCE; VASCULAR RING; VASODILATATION;

ANIMALIA;

EID: 0038070254     PISSN: 00916765     EISSN: None     Source Type: Journal    
DOI: 10.1289/ehp.5916     Document Type: Article

References (35)

1. Alexander RW. 1995. Hypertension and the pathogenesis of atherosclerosis: oxidative stress and the mediation of arterial inflammatory response: a new perspective. Hypertension 25:155-161.
2. Bagla P, Kaiser J. 1996. India's spreading health crisis draws global arsenic experts. Science 274:174-175.
3. Bates MN, Smith AH, Hopenhayn-Rich C. 1992. Arsenic ingestion and internal cancers: a review. Am J Epidemiol 135:462-476.
4. Bell DM, Johns TE, Lopez LM. 1998. Endothelial dysfunction: implications for therapy of cardiovascular diseases. Ann Pharmacother 32:459-470.
5. Bredt DS, Snyder SH. 1990. Isolation of nitric oxide synthetase, a calmodulin-requiring enzyme. Proc Natl Acad Sci U S A 87:682-685.
6. Carmignani M, Boscolo P, Castellino, N. 1985. Metabolic fate and cardiovascular effects of arsenic in rats and rabbits chronically exposed to trivalent and pentavalent arsenic. Arch Toxicol Suppl 8:452-455.
7. Chan PC, Huff J. 1997. Arsenic carcinogenesis in animals and in humans: mechanistic, experimental, and epidemiological evidence. J Environ Sci Health, Part C: Environ Carcinog Ecotoxicol Rev 15:83-122.
8. Chen CJ, Wu MM, Lee SS, Wang JD, Cheng SH, Wu HY. 1988. Atherogenicity and carcinogenicity of high-arsenic artesian well water. Multiple risk factors and related malignant neoplasms of blackfoot disease. Arteriosclerosis 8:452-460.
9. Chiou HY, Huang WI, Su CL, Chang SF, Hsu YH, Chen CJ. 1997. Dose-response relationship between prevalence of cerebrovascular disease and ingested inorganic arsenic. Stroke 28:1717-1723.
10. Col M, Col C, Soran A, Sayli BS, Ozturk S. 1999. Arsenic-related Bowen's disease, palmar keratosis, and skin cancer. Environ Health Perspect 107:687-689.
11. Del Razo LM, Quintanilla-Vega B, Brambila-Colombres E, Calderon-Aranda ES, Manno M, Albores A. 2001. Stress proteins induced by arsenic. Toxicol Appl Pharmacol 177:132-148.
12. Engel RR, Hopenhayn-Rich C, Receveur O, Smith AH. 1994. Vascular effects of chronic arsenic exposure: a review. Epidemiol Rev 16:184-209.
13. Heydorn K. 1970. Environmental variation of arsenic levels in human blood determined by neutron activation analysis. Clin Chim Acta 28:349-357.
14. Ignarro LJ. 1989. Heme-dependent activation of soluble guanylate cyclase by nitric oxide: regulation of enzyme activity by porphyrins and metalloporphyrins. Semin Hematol 26:63-76.
15. Knoepp L, Beall A, Woodrum D, Mondy JS, Shaver E, Dickinson M, et al. 2000. Cellular stress inhibits vascular smooth muscle relaxation. J Vasc Surg 31:343-353.
16. Lee JY, Bae ON, Chung SM, Lee MY, Chung JH. 2001. Menadione induces endothelial dysfunction mediated by oxidative stress and arylation. Chem Biol Interact 137:169-183.
17. Lee MY, Bae ON, Chung SM, Kang KT, Lee JY, Chung JH. 2002. Enhancement of platelet aggregation and thrombus formation by arsenic in drinking water: a contributing factor to cardiovascular disease. Toxicol Appl Pharmacol 179:83-88.
18. Lefer AM, Tsao PS, Lefer DJ, Ma XL. 1991. Role of endothelial dysfunction in the pathogenesis of reperfusion injury after myocardial ischemia. FASEB J 5:2029-2034.
19. Lowry OH, Rosenberg NJ, Farr AL, Randall RJ. 1951. Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
20. Luscher TF, Tanner FC, Tschundi MR, Noll G. 1993. Endothelial dysfunction in coronary artery disease. Annu Rev Med 44:395-418.
21. Lynn S, Gurr JR, Lai HT, Jan KY. 2000. NADH oxidase activation is involved in arsenite-induced oxidative DNA damage in human vascular smooth muscle cells. Circ Res 86:514-519.
22. Moncada S, Palmer RM, Higgs EA. 1991. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 43:109-142.
23. NRC (National Research Council). 1999. Chemistry and analysis of arsenic species in water, food, urine, blood, hair, and nails. In: Arsenic in Drinking Water (National Research Council, ed). Washington, DC:National Academy Press, 27-82.
24. Pi J, Kumagai Y, Sun G, Yamauchi H, Yoshida T, Iso H, et al. 2000. Decreased serum concentrations of nitric oxide metabolites among Chinese in an endemic area of chronic arsenic poisoning in inner Mongolia. Free Radic Biol Med 28:1137-1142.
25. Pryor WA, Squadrito GL. 1995. The chemistry of peroxynitrite: a product from the reaction of nitric oxide with superoxide. Am J Physiol 268:L699-L722.
26. Rahman M, Tondel M, Ahmad SA, Chowdhury IA, Faruquee MH, Axelson O. 1999. Hypertension and arsenic exposure in Bangladesh. Hypertension 33:74-78.
27. Robertson BE, Schubert R, Hescheler J, Nelson MT. 1993. cGMP-dependent protein kinase activates Ca-activated K channels in cerebral artery smooth muscle cells. Am J Physiol 265:C299-C303.
28. Rubanyi GM. 1993. The role of endothelium in cardiovascular homeostasis and diseases. J Cardiovasc Pharmacol 22(suppl 4):S1-S14.
29. Sellke FW, Boyle EM, Verrier ED. 1997. The pathophysiology of vasomotor dysfunction. Ann Thorac Surg 64:S9-S15.
30. Smith KR, Klei LR, Barchowsky A. 2001. Arsenite stimulates plasma membrane NADPH oxidase in vascular endothelial cells. Am J Physiol Lung Cell Mol Physiol 280:L442-L449.
31. Tseng CH, Tai TY, Chong CK, Tseng CP, Lai MS, Lin BJ, et al. 2000. Long-term arsenic exposure and incidence of non-insulin-dependent diabetes mellitus: a cohort study in arseniasis-hyperendemic villages in Taiwan. Environ Health Perspect 108:847-851
32. Tseng WP. 1977. Effects and dose-response relationships of skin cancer and blackfoot disease with arsenic. Environ Health Perspect 19:109-119.
33. Vanhoutte PM. 1997. Endothelial dysfunction and atherosclerosis. Eur Heart J 18(suppl E):E19-E29.
34. Wang CH, Jeng JS, Yip PK, Chen CL, Hsu LI, Hsueh YM, et al. 2002. Biological gradient between long-term arsenic exposure and carotid atherosclerosis. Circulation 105:1804-1809.
35. Wanstall JC, Jeffery TK, Gambino A, Lovren F, Triggle CR. 2001. Vascular smooth muscle relaxation mediated by nitric oxide donors: a comparison with acetylcholine, nitric oxide and nitroxyl ion. Br J Pharmacol 134:463-472.